Inserm, UMR1053 Bordeaux research in translational oncology, BaRITOn, université de Bordeaux, 33076 Bordeaux, France; Service of Clinical Pathology, Lausanne University Hospital, Institute of Pathology, 25 rue du Bugnon, CH-1011 Lausanne, Switzerland.
Service of Clinical Pathology, Lausanne University Hospital, Institute of Pathology, 25 rue du Bugnon, CH-1011 Lausanne, Switzerland.
Clin Res Hepatol Gastroenterol. 2019 Feb;43(1):12-19. doi: 10.1016/j.clinre.2018.07.007. Epub 2018 Sep 10.
Hepatocellular adenomas (HCA) are rare benign hepatocellular tumors occurring mainly in women taking oral contraceptives with 2 major complications: severe bleeding and malignant transformation that can be avoided if nodules exceeding 5 cm are resected. This simple attitude has been challenged in the recent years with HCA in men, in young adolescent, in aged persons, and complications in hepatocellular adenomas below 5 cm. The discovery of specific mutations leading to specific phenotypes has modified the clinical spectrum of the disease. The phenotypic immune classification of HCA based on the molecular classification is being widely used in liver referral centers. The aim of this snapshot is to briefly present for each subtype the clinical, pathological, immuno-pathological criteria as well as the risk of complications and guidelines for treatment and management.
肝细胞腺瘤（HCA）是一种罕见的良性肝细胞肿瘤，主要发生在服用口服避孕药的女性中，有 2 种主要并发症：严重出血和恶性转化，如果结节超过 5cm，则可避免这些并发症。近年来，男性、青少年、老年人中的 HCA 以及直径小于 5cm 的 HCA 并发症对这种简单的态度提出了挑战。导致特定表型的特定突变的发现改变了疾病的临床谱。基于分子分类的 HCA 表型免疫分类已在肝脏转诊中心广泛应用。本快照的目的是简要介绍每种亚型的临床、病理、免疫病理标准以及并发症风险和治疗管理指南。
